Online inquiry

IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13928MR)

This product GTTS-WQ13928MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Fibrodysplasia ossificans prograssiva (FOP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13928MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15997MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ13378MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PR-1498487
GTTS-WQ1566MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ14882MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ13889MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ9293MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ3338MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ7952MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW